MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Ambulosono: A Novel Sensor-based System for Quantitative Evaluation Freezing of Gait in Parkinson’s disease

    W. Xian, B. Hu, L. Chen, Z. Pei (Guangzhou, China)

    Objective: We prospectively evaluated the manifestations of On-Drug freezing of gait (FOG) of Parkinson’s disease (PD) in China using a novel sensor-based system. Background: FOG…
  • MDS Virtual Congress 2020

    Effect of Lactobacillus casei supplementation on clinical response, gut microbiota and faecal metabolites in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial

    X.D Yang, X.Q He, S.Q Xu, VV. Qian, Y. Zhang, YY. Song, Q. Xiao (Shanghai, China)

    Objective: To evaluate the effect of Lactobacillus casei strain Shirota (LcS) supplementation on symptoms, gut microbiota and faecal metabolites in patients with Parkinson's disease (PD).…
  • MDS Virtual Congress 2020

    Using a Delphi process to inform the design of disease modifying trials in Parkinson’s disease

    M. Zeissler, R. Windle, K. McFarthing, K. Raphael, G. Rafaloff, C. Carroll (Plymouth, United Kingdom)

    Objective: To consolidate current opinion on trial methodology of disease modifying therapies (DMTs) for Parkinson’s disease (PD) and establish consensus on a core protocol for…
  • MDS Virtual Congress 2020

    Opicapone study in daily clinical practice. OPRA study

    J. Abril Jaramillo, J. Rodriguez, H. Perez (Sevilla, Spain)

    Objective: Improvement of off time and increase of ON time without dyskinesias at 6 months compared to the baseline situation. Secondary Endpoints: Determine the rate…
  • MDS Virtual Congress 2020

    Andrograholide protect microglial activation via inhibiting mitochondrial ROS generation and NLRP3 inflammasome activation in in-vitro and in-vivo model of Parkinson’s disease

    S. Ahmed, V. Naidu (Kamrup, India)

    Objective: Parkinson's disease (PD) is a distressing neurodegenerative disorder effecting nearly 2-3% of the total population greater than 65 years old . Several mechanisms have…
  • MDS Virtual Congress 2020

    Real-World Data on the Use of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease who are Treated with Deep Brain Stimulation: The PD-DUAL Study

    J. Aldred, F. Amjad, A. Johnson, P. Kukreja, I. Malaty, S. Parashos, J. Siddiqui, M. Siddiqui, J. Zamudio, S. Thakkar (Spokane, WA, USA)

    Objective: To examine the use of oral anti-parkinsonian medications in advanced Parkinson’s disease (APD) patients who have a history of, or current treatment with deep…
  • MDS Virtual Congress 2020

    Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson’s disease patients with motor fluctuations

    A. Antonini, G. Ebersbach, O. Rascol, F. Ikedo, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations being treated with different levodopa-containing treatment regimens. Background: OPC,…
  • MDS Virtual Congress 2020

    Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II

    A. Antonini, W. Poewe, J. Ferreira, G. Ebersbach, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the efficacy and safety of opicapone (OPC) in Parkinson’s disease (PD) patients who were considered ‘super-responders’ (>= 2 hours of OFF-time reduction…
  • MDS Virtual Congress 2020

    Opicapone in fluctuating Parkinson’s disease: The daily clinical practice

    L. Armengou Garcia, G. Martí-Andrés, R. Valentí Azcárate, I. Esparragosa Vázquez, C. Toledano Illán, R. Villino Boquete, R. Luquin (Pamplona, Spain)

    Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…
  • MDS Virtual Congress 2020

    Refining Knowledge on the Treatment of Pisa Syndrome with Botulinum Toxin

    C.A Artusi, F. Marchet, U. Dimanico, C. Zanella, M. Zibetti, A. Merola, G. Massazza, L. Lopiano (Torino, Italy)

    Objective: To analyze the efficacy of botulinum toxin (BoNT) in cases of pisa syndrome (PS) associated with Parkinson's disease (PD) targeting paraspinal muscles ipsilateral to…
  • « Previous Page
  • 1
  • …
  • 1132
  • 1133
  • 1134
  • 1135
  • 1136
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley